Table 5 Multivariable Cox Proportional Hazards Model National Cancer Data Base 2010–2017 Patients ≥70 with cT1-3/cN0-3, Triple Negative or HER2 Positive invasive breast cancer treated with surgery and/or chemotherapy Adjusted for age, clinical T stage, clinical N stage, hormone receptors status, and comorbidity (N = 2326)

From: Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer

Variable

Hazard ratio

95% confidence interval

p-Value

Age (per year increase)

1.04

1.03–1.05

≤.0001

Clinical T stage (cT)

 T1

Reference

 

≤.0001

 T2

1.57

1.37–1.81

 

 T3

2.25

1.81–2.79

 

Clinical N stage (cN)

   

 N0

Reference

 

≤.001

 N1

1.33

1.14–1.55

 

 N2/3

1.71

1.31–2.21

 

Year of diagnosis

  

0.15

 2010–2012

Reference

  

 2013–2015

0.90

0.79–1.03

 

 2016–2017

0.80

0.66–0.97

 

Hormone Receptor

   

 Negative

Reference

 

≤.001

 Positive

0.65

0.52–0.82

 

Charlson/Deyo Score

 2

Reference

 

<0.001

 3

1.25

1.09–1.42

 

Treatment

 Surgery only

Reference

 

<0.0001

 Chemotherapy→Surgery

0.47

0.36–0.61

 

 Surgery → Chemotherapy

0.55

0.47–0.64

 

 Chemotherapy alone

1.46

1.05–2.04

 
  1. *The Charlson/Deyo value is a weighted score derived from the sum of the scores for comorbid conditions. Comorbid conditions with a score of 1 include myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, or diabetes. Comorbid conditions with a score of 2 include a single diagnosis of diabetes with complications, hemiplegia/paraplegia, or renal disease. Comorbid conditions with a score of 3 include moderate /severe liver disease or AIDS. A cumulative score of ≥3 is classified as a Charslon/Deyo score of 3.
  2. **The American Joint Committee on Cancer Breast Cancer Staging Edition 7 was used for this analysis.
Back to article page